Small Molecules

09 Jan 2020 Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
09 Jan 2020 AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise
09 Jan 2020 OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
08 Jan 2020 PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
08 Jan 2020 Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones
08 Jan 2020 Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma
07 Jan 2020 Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
07 Jan 2020 AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain
07 Jan 2020 InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab
07 Jan 2020 Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis
07 Jan 2020 Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME
06 Jan 2020 CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
06 Jan 2020 ESCAPE Bio Announces Excellent Safety and Tolerability in Phase 1 Study of Oral S1P5 Receptor Agonist ESB1609
06 Jan 2020 Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency
06 Jan 2020 Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
03 Jan 2020 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
02 Jan 2020 Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)
02 Jan 2020 RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
02 Jan 2020 Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
02 Jan 2020 DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
01 Jan 2020 Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
01 Jan 2020 X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)
30 Dec 2019 Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
30 Dec 2019 BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
30 Dec 2019 Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up